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Lymphadenectomy and risk of 
reoperation or mortality shortly 
after surgery for oesophageal 
cancer
Jesper Lagergren1,2, Fredrik Mattsson1, Andrew Davies1,2, Mats Lindblad3 & 
Pernilla Lagergren4
The prognostic role of lymphadenectomy during surgery for oesophageal cancer is questioned. We 
aimed to test whether higher lymph node harvest increases the risk of early postoperative reoperation 
or mortality. A population-based cohort study including almost all patients who underwent resection 
for oesophageal cancer in Sweden in 1987–2010. Data were collected from medical records and well-
established nationwide Swedish registries. The exposures were number of removed lymph nodes 
(primary) and number of node metastases (secondary). The main study outcome was reoperation/
mortality within 30 days of primary surgery. Relative risks (RRs) with 95% confidence intervals (CIs) were 
calculated using Poisson regression, adjusted for age, sex, co-morbidity, neoadjuvant therapy, tumour 
stage, tumour histology, surgeon volume, and calendar period. Among 1,820 participants, the risk of 
reoperation/mortality did not increase with greater lymph node harvest (RR = 0.98, 95%CI 0.96–1.00, 
discrete variable) or with greater number of removed metastatic nodes (RR = 1.00, 95% CI 0.95–1.05, 
discrete variable). Similarly, in stratified analyses within pre-defined categories of tumor stage, surgeon 
volume and calendar period, increased number of removed nodes or node metastases did not increase 
the risk of reoperation/mortality. Lymphadenectomy during oesophageal cancer surgery is a safe 
procedure in the short term perspective.
Oesophageal cancer is one of the most common and deadly cancer types, and it is the 6th most common cause of 
cancer death globally1. Surgical resection is the cornerstone of the curatively intended treatment of oesophageal 
cancer and survival following oesophagectomy has improved over the last few decades2. This improvement is 
likely due to multiple factors, including improvements in patient selection, perioperative care and centralisation 
of services. Yet, only 30% of patients survive 5 years following surgery according to recent population-based data3, 
which stresses the need to identify factors that can further optimise surgical treatment. The extent of lymph node 
removal might be a relevant factor in this respect. Although based on a limited body of evidence, the use of a fairly 
extensive (2-field) lymphadenectomy is generally recommended4–6. However, the independent prognostic role of 
lymphadenectomy has been questioned in two recent studies from our research group7,8. The possible lack of an 
independent association between lymph node harvest and long-term prognosis highlights the need to also exam-
ine the role of lymphadenectomy in relation to serious short-term outcomes, caused by postoperative complica-
tions. We hypothesized that the additional surgical trauma associated with a more extensive lymphadenectomy 
increases the risk of postoperative complications requiring reoperation, or leading to mortality within 30 days 
of oesophagectomy. To test this hypothesis, we conducted a population-based nationwide Swedish cohort study.
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Results
Patients. The entire study cohort included 1 820 patients who underwent surgical resection for oesophageal 
cancer. Among these, 1 434 patients (79%) had complete data on all study exposures, covariates and outcomes, 
and were thus selected for the complete case analysis. Since the results were very similar for the entire cohort 
(imputation of missing data) and the cohort with all data available (complete case analysis), we present only the 
results for the entire cohort. Characteristics of the patients categorised into quartiles of number of lymph nodes 
are presented in Table 1. A greater number of removed nodes were associated with higher surgeon volume and 
more recent calendar period.
Lymph node harvest and 30-day postoperative outcomes. An increased lymph node harvest did 
not increase the risk of reoperation/mortality within 30 days of surgery (Table 2). When the total number of 
lymph nodes was analysed as a discrete variable the RR was 0.98 (95% CI 0.96–1.00) and the corresponding RR 
for number of metastatic nodes was 1.00 (95% CI 0.95–1.05). Comparing the highest quartile of lymph node yield 
and node metastases with the lowest two quartiles produced RRs of 0.80 (95% CI 0.51–1.26) and 0.85 (95% CI 
0.56–1.27), respectively. There were no statistically significant associations between number of lymph nodes or 
node metastases and any of the six outcomes when analysed separately (Table 2). In analyses stratified by cate-
gories of tumour stage, surgeon volume and calendar period, an increased lymph node harvest did not entail an 
increased risk of reoperation/mortality within 30 days of oesophagectomy (Table 3).
Discussion
This study did not support the hypothesis of an increased risk of 30-day postoperative reoperation or mortality 
associated with an increased total number of lymph nodes or increased number of metastatic nodes removed.
Methodological advantages of the study include the population-based design with a high participation rate, 
robust assessment of exposures and outcomes, and the adjustment for several potential confounding factors. 
These factors counteract bias from selection, misclassification, and confounding, respectively. One can discuss 
whether reoperation is a good assessment of complications, but we deemed that the validity of this variable was 
substantially higher than evaluating individual complications that might easily have been missed in the discharge 
Number of lymph nodes in quartiles
1st/2nd (0–7) 
Patients, N 
(%)
3rd (8–15) 
Patients, N 
(%)
4th (16–114) 
Patients, N 
(%)
Missing 
Patients, N 
(%)
Total 772 (100) 375 (100) 323 (100) 350 (100)
Mean age (standard deviation) 65 (10) 65 (9) 66 (9) 66 (10)
Sex
Male 578 (75) 284 (76) 246 (76) 252 (72)
Female 194 (25) 91 (24) 77 (24) 98 (28)
Co-morbidity score
0 490 (63) 202 (54) 155 (48) 217 (62)
1 144 (19) 84 (22) 77 (24) 70 (20)
> 1 138 (18) 89 (24) 91 (28) 63 (18)
Tumor stage
0-I 205 (27) 78 (21) 57 (18) 82 (23)
II 297 (38) 120 (32) 116 (36) 129 (37)
III-IV 270 (35) 176 (47) 149 (46) 127 (36)
Missing 0 (0) 1 (0) 1 (0) 12 (3)
Tumor histology
Adenocarcinoma 290 (38) 194 (52) 172 (53) 136 (39)
Squamous 482 (62) 181 (48) 151 (47) 210 (60)
Missing 0 (0) 0 (0) 0 (0) 4 (1)
Neoadjuvant therapy
No 490 (63) 271 (72) 244 (76) 224 (64)
Yes 282 (37) 104 (28) 79 (24) 124 (35)
Missing 0 (0) 0 (0) 0 (0) 2 (1)
Surgeon volume 
< 17 427 (55) 158 (42) 99 (31) 203 (58)
≥ 17 321 (42) 210 (56) 222 (69) 131 (37)
Missing 24 (3) 7 (2) 2 (1) 16 (5)
Calendar period
1987–1999 540 (70) 120 (32) 22 (7) 310 (89)
2000–2010 232 (30) 255 (68) 301 (93) 40 (11)
30-day reoperation/mortality 127 (16) 43 (11) 32 (10) 69 (20)
30-day mortality 49 (6) 10 (3) 7 (2) 32 (9)
30-day reoperation 91 (12) 36 (10) 26 (8) 47 (13)
Anastomotic leak 12 (2) 10 (3) 11 (3) 1 (0)
Laparotomy 25 (3) 10 (3) 7 (2) 15 (4)
Wound infection 24 (3) 3 (1) 1 (0) 14 (4)
Table 1. Characteristics of 1820 patients who underwent surgical resection for esophageal cancer in 
Sweden in 1987–2010, categorized for total number of lymph nodes removed.
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records, while reoperations are not. An obvious confounding factor in this study is surgeon volume, since sur-
geons with a higher annual volume of oesophagectomy also typically remove more lymph nodes and have better 
short-term outcomes than less experienced surgeons7,9. Therefore, we adjusted for annual surgeon volume in the 
multivariable model and also performed stratified analyses among surgeons above and below the median vol-
ume. Yet, we cannot entirely exclude residual confounding, e.g. due to rough categorization or misclassification. 
Another methodological issue is that reoperation and mortality are competing events, since mortality occurring 
before any potential later reoperation is not accounted for. Therefore, the combined reoperation/mortality out-
come was selected as the main study outcome, while the results regarding the separate reoperation outcomes 
should be interpreted with caution. We used 30-day outcomes to avoid including reoperations for later compli-
cations that tend to be less severe, and the use of 30-day mortality rather than 90-day mortality was because this 
study focused on reoperations but included mortality because of the issue of competing events. Another source 
of error is missing data on some variables, including the lymph node variables. To account for this we used both 
imputation analysis (imputation where data were missing) and complete case analysis (including only patients 
with data on all variables). The similar results using both these analytical approaches indicate that the presence of 
missing data did not strongly influence the results of the study. Another source of error is misclassification of the 
assessment of the number of lymph nodes removed, which could differ between histopathologists. Such misclas-
sification should be random, and thus dilute potential associations. However, our previous study on lymph node 
removal and long-term prognosis revealed strong associations between lymph node metastases and mortality, 
which lends validity to the node assessment7. Finally, despite the large sample size, the relatively low frequency of 
the study outcomes reduced the statistical precision, particularly in the subgroup analyses.
Two recent studies from our group indicate a lack of long-term prognostic benefit from a higher lymph node 
yield during surgery for oesophageal cancer after controlling for surgeon volume7,8. One was based on nationwide 
Swedish data7, and the other was based on data from a high-volume center for oesophageal cancer surgery in 
London, the United Kingdom8. On the other hand, the results from the present study indicate that a more exten-
sive lymph node dissection might not be harmful. The lack of increased risk of serious poor short-term outcomes 
following a more extensive lymphadenectomy needs to be confirmed in future research before any clinical recom-
mendations can be made. Although the volume of resected tissue can vary substantially between two surgeons, 
it is possible that standardization of the lymph node dissection after having conducted a substantial number of 
oesophagectomies makes this dissection quite safe. The issues following the additional surgical trauma associated 
with a more extensive lymphadenectomy might be counteracted by the increasing surgeon experience that tends 
to parallel the extent of lymph node removal.
In conclusion, this large and population-based cohort study provides no evidence that a more extensive lym-
phadenectomy increases the risk of reoperation or mortality within 30 days of primary resectional surgery for 
oesophageal cancer. Thus, lymphadenectomy can be regarded a safe procedure in the short term.
Methods
Design. The study was designed and analyzed according to a detailed study protocol which was developed 
and completed prior to the initiation of the study. Earlier versions of our nationwide Swedish cohort for oesoph-
ageal cancer surgery have been described in detail elsewhere2,7,10. In brief, the study cohort included virtually all 
patients (98%) who underwent open thoraco-abdominal resection for oesophageal cancer in Sweden during the 
period 1987 to 2010. The study exposures were the total number of lymph nodes removed and the number of 
Reoperation/mortality  
(271 patients)
Mortality  
(98 patients)
Reoperation 
(200 patients)
Anastomotic leak 
(34 patients)
Laparotomy 
(57 patients)
Wound infection 
(42 patients)
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Number of nodes
Discrete variable 
(0–114)b 0.98 (0.96–1.00) 0.97 (0.93–1.01) 0.98 (0.96–1.01) 1.01 (0.98–1.04) 1.00 (0.96–1.04) 0.96 (0.88–1.04)
Quartile 1st and 
2nd (0–7) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Quartile 3rd 
(8–15) 0.84 (0.59–1.21) 0.60 (0.31–1.18) 0.90 (0.60–1.36) 1.39 (0.57–3.44) 1.26 (0.58–2.74) 0.54 (0.17–1.74)
Quartile 4th 
(16–114) 0.80 (0.51–1.26) 0.63 (0.26–1.55) 0.79 (0.47–1.33) 1.39 (0.54–3.62) 1.28 (0.48–3.38) 0.48 (0.06–3.64)
Number of metastatic nodes
Discrete variable 
(0–44)b 1.00 (0.95–1.05) 1.00 (0.92–1.09) 1.00 (0.94–1.05) 1.08 (1.02–1.15) 1.04 (0.95–1.13) 0.99 (0.86–1.14)
Quartile 1st and 
2nd (0–1) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Quartile 3rd 
(2–3) 1.04 (0.69–1.57) 1.14 (0.56–2.32) 1.03 (0.65–1.65) 0.62 (0.18–2.21) 1.07 (0.41–2.77) 1.24 (0.43–3.57)
Quartile 4th 
(4–44) 0.85 (0.56–1.27) 0.95 (0.50–1.82) 0.78 (0.48–1.26) 0.90 (0.32–2.59) 1.07 (0.45–2.55) 1.02 (0.37–2.83)
Table 2. Lymph node harvest and risk of reoperation/mortality and other outcomes within 30 days of 
surgery for esophageal cancer (n = 1820), expressed as relative risk (RR) with 95% confidence interval 
(CI)a. aAdjusted for age, sex, tumor stage, Charlson co-morbidity score, neoadjuvant therapy, tumor histology, 
surgeon volume, and calendar period. bIncluded in the model as a discrete variable to evaluate linear trend.
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lymph node metastases removed. Data on lymph node harvest were retrieved from the histopathology records of 
the resected tumour specimens throughout Sweden. The main study outcome was reoperation/mortality occur-
ring within 30 days of primary oesophagectomy. Secondary outcomes were reoperation (for any reason), reoper-
ation for anastomotic leakage, reoperation with laparotomy, reoperation for wound infection, and mortality, all 
within 30 days of the primary surgery. The data for assessing reoperation and mortality were collected from the 
Swedish Patient Registry (operation codes) and the Swedish Causes of Death Registry (date of death), respec-
tively. Data on all relevant clinical variables as potential confounders (presented below) were retrieved from 
medical records, mainly histopathology records and operation charts.
Approvals. The study and the study protocol were approved by the institutional and licensing committee, i.e. 
the Regional Ethical Review Board in Stockholm (reference number 12/537–32). All methods were carried out in 
accordance with relevant guidelines and regulations. Informed consent was not obtained since this is not required 
for this type of study (based on registry data and medical records) according to Swedish law.
Statistical analysis. The number of lymph nodes and the number of lymph node metastases were analyzed 
both as continuous variables and categorical variables (quartiles) in relation to risk of the study outcomes. Since 
the number of nodes and node metastases was low in the first and second quartiles, these were collapsed into 
one group. Poisson regression was used to calculate relative risks (RRs) with 95% confidence intervals (CIs). 
Log-transformed person-time was included in the model as an offset. We assumed that each individual contrib-
uted the same weight towards person-time. RRs were adjusted for eight variables that were selected as potential 
confounders based on previous research: 1) age (continuous variable), 2) sex (categorized into male or female), 
3) tumor stage (0-I, II or III-IV), 4) co-morbidity (Charlson co-morbidity index11: 0, 1 or > 1), 5) neoadjuvant 
oncological therapy (yes or no), 6) histological tumour type (adenocarcinoma or squamous cell carcinoma), 7) 
annual surgeon volume of oesophagectomies (< 17 or ≥ 17), and 8) calendar period (1987–1999 or 2000–2010). 
Furthermore, six more variables were created with a combination of either number of lymph nodes or the number 
of lymph node metastases and tumor stage (0-I, II and III-IV), annual surgeon volume of oesophagectomies 
(< 17 and ≥ 17) and calendar period of surgery (1987–1999 and 2000–2010). These analyses were conducted 
to evaluate if the association between either number of lymph nodes or the number of lymph node metastases 
and the outcome reoperation/mortality might change depending on tumour stage, annual surgeon volume and 
calendar time. To handle missing data on exposures or covariates, we conducted both multiple imputation (using 
the entire cohort while imputing missing data) and complete case analysis (using only patients for whom all var-
iables were available). Twenty data sets were imputed in the multiple imputation analysis. The monotone logistic 
method in PROC MI was used on the assumption that the missing data were missing at random (MAR)12. The 
variables included in the imputation were the eight potential confounders presented above, one of the exposures 
and one of the outcomes, depending on the model. Furthermore, PROC MIANALYZE was used to combine the 
results from the analyses of the 20 datasets. The underlying assumption was evaluated by means of sensitivity 
analyses utilizing pattern-mixture models using the statement ‘missing not at random’. The statistical software 
SAS version 9.4 (SAS Institute, Cary, NC) was used for all data management and statistical analysis.
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